Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum.

•Treating ALK+ NSCLC in pregnancy is delicate due to scarce data on tyrosine kinase inhibitors (TKI) fetotoxicity.•Postpartum period might render ALK+ NSCLC patients especially vulnerable to toxicity.•This is the first case of globus pallidus necrosis while on TKI therapy in ALK+ NSCLC.•Patients with previous pneumonitis from other TKI can tolerate exposure to brigatinib.